About Nouscom
Nouscom is a company based in Basel (Switzerland) founded in 2015.. Nouscom has raised $151.98 million across 4 funding rounds from investors including EQT, Bpifrance and Andera Partners. Nouscom offers products and services including NOUS-209, NOUS-PEV, and Endovax. Nouscom operates in a competitive market with competitors including Replimune, VBI Vaccines, Candel Therapeutics, SillaJen and Adlai Nortye, among others.
- Headquarter Basel, Switzerland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nouscom Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$151.98 M (USD)
in 4 rounds
-
Latest Funding Round
$7.61 M (USD), Series C
Mar 21, 2024
-
Investors
EQT
& 12 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nouscom
Nouscom offers a comprehensive portfolio of products and services, including NOUS-209, NOUS-PEV, and Endovax. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Off-the-shelf vaccine for mismatch repair deficient tumors.
Tailored neoantigen vaccine for individual solid tumors.
Targeted virus with immune-modulators for solid tumor treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of Nouscom
Nouscom has successfully raised a total of $151.98M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $7.61 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $7.6M
-
First Round
First Round
(17 May 2016)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Series C - Nouscom | Valuation |
investors |
|
| Nov, 2023 | Amount | Series C - Nouscom | Valuation | Andera Partners , Bpifrance | |
| Nov, 2017 | Amount | Series B - Nouscom | Valuation | Abingworth |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nouscom
Nouscom has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, Bpifrance and Andera Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Angelini Ventures is focused on investing in BioTech and Digital Health.
|
Founded Year | Domain | Location | |
|
Capital is provided to firms for growth, buyouts, and acquisitions.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nouscom
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nouscom
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nouscom Comparisons
Competitors of Nouscom
Nouscom operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Replimune, VBI Vaccines, Candel Therapeutics, SillaJen and Adlai Nortye, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of oncolytic immunotherapies
|
|
| domain | founded_year | HQ Location |
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
|
| domain | founded_year | HQ Location |
Viral immunotherapies are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Oncolytic immunotherapeutics are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Immune oncolytic therapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic vaccines for cancer and infectious diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nouscom
Frequently Asked Questions about Nouscom
When was Nouscom founded?
Nouscom was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Nouscom located?
Nouscom is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Is Nouscom a funded company?
Nouscom is a funded company, having raised a total of $151.98M across 4 funding rounds to date. The company's 1st funding round was a Series B of $48.79M, raised on May 17, 2016.
What does Nouscom do?
Founded in 2015 and based in Basel, Switzerland, the company operates in the biotechnology sector, where viral-vector-based vaccines for cancer treatment are developed. Two product candidates are advanced: Endovax, an antigen-less vaccine utilizing oncolytic viruses that replicate selectively in cancer cells to trigger immunogenic cell death and mobilize T cells at tumor sites; and Exovax, a patient-specific vaccine employing viral vectors to encode neo-antigens for expanding targeted T cells.
Who are the top competitors of Nouscom?
Nouscom's top competitors include Replimune, VBI Vaccines and Candel Therapeutics.
What products or services does Nouscom offer?
Nouscom offers NOUS-209, NOUS-PEV, and Endovax.
Who are Nouscom's investors?
Nouscom has 13 investors. Key investors include EQT, Bpifrance, Andera Partners, Revelation Partners, and Abingworth.